- Home
- BEAM vs ARCO Comparison
BEAM vs ARCO Comparison
Compare BEAM & ARCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- ARCO
- Stock Information
- Founded
- BEAM 2017
- ARCO 2007
- Country
- BEAM United States
- ARCO Uruguay
- Employees
- BEAM N/A
- ARCO N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- ARCO Restaurants
- Sector
- BEAM Health Care
- ARCO Consumer Discretionary
- Exchange
- BEAM Nasdaq
- ARCO Nasdaq
- Market Cap
- BEAM 1.8B
- ARCO 1.5B
- IPO Year
- BEAM 2020
- ARCO 2011
- Fundamental
- Price
- BEAM $17.41
- ARCO $8.03
- Analyst Decision
- BEAM Strong Buy
- ARCO Buy
- Analyst Count
- BEAM 11
- ARCO 1
- Target Price
- BEAM $48.90
- ARCO $12.00
- AVG Volume (30 Days)
- BEAM 2.2M
- ARCO 1.6M
- Earning Date
- BEAM 05-06-2025
- ARCO 05-14-2025
- Dividend Yield
- BEAM N/A
- ARCO 2.99%
- EPS Growth
- BEAM N/A
- ARCO N/A
- EPS
- BEAM N/A
- ARCO 0.71
- Revenue
- BEAM $63,578,000.00
- ARCO $4,470,162,000.00
- Revenue This Year
- BEAM N/A
- ARCO $6.66
- Revenue Next Year
- BEAM $6.32
- ARCO $8.58
- P/E Ratio
- BEAM N/A
- ARCO $11.30
- Revenue Growth
- BEAM N/A
- ARCO 3.19
- 52 Week Low
- BEAM $13.53
- ARCO $6.66
- 52 Week High
- BEAM $35.25
- ARCO $11.35
- Technical
- Relative Strength Index (RSI)
- BEAM 43.14
- ARCO 60.68
- Support Level
- BEAM $15.51
- ARCO $7.48
- Resistance Level
- BEAM $20.90
- ARCO $7.72
- Average True Range (ATR)
- BEAM 1.22
- ARCO 0.19
- MACD
- BEAM -0.03
- ARCO 0.08
- Stochastic Oscillator
- BEAM 35.25
- ARCO 85.09
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About ARCO Arcos Dorados Holdings Inc. Shares
Arcos Dorados Holdings Inc operates McDonald's-branded restaurants in approximately 20 countries and territories in Latin America and the Caribbean. It functions through two sources which include company-operated restaurants and franchised restaurants segment. Their menu includes hamburgers, McNuggets, salad, sandwiches, french fries and others.